BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.

1/4
BioStar News
Portfolio News

July 14, 2019

BioStar Capital Expands VC Fund to $91 Million

>> Read More

October 10, 2016

Professor Ian Meredith, Cardiovascular Medical Venture Partner for BioStar, To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer

>> Read More

September 17, 2019

Foldax®, Inc. Successfully Completes First-In-Human Use of Next-Generation Tria Polymer Heart Valve for the Treatment of Aortic Valve Disease

>> Read More

September 17, 2019

Beaumont doctors implant world’s first Tria flexible polymer heart valve

>> Read More

Active Portfolio Companies
ASI Logo - New.png
cathworks_logo-01.jpg
NewPace
V-Wave
Trice Logo - New.png
Vytronus - New.png